5-MeO-DPT Stats & Data
CCCN(CCC)CCc1cnc2ccc(OC)cc12PNHPVNBKLQWBKH-UHFFFAOYSA-NReceptor Profile
Receptor Actions
Effect Profile
Curated + 8 ReportsModerate visuals with mild headspace and auditory effects, low body load
Tolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Pattern inferred from broader serotonergic psychedelic use: noticeable tolerance if re‑used within 24–72 h; ~1–2 weeks commonly restores much of sensitivity; 2–3 weeks usually returns to baseline. Data quality: anecdotal/community consensus rather than controlled studies.
Cross-Tolerances
Experience Report Analysis
ErowidDemographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 8 experience reports (8 Erowid)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 8
Adverse Effects 3
Real-World Dose Distribution
62K DosesFrom 10 individual dose entries
Oral (n=6)
Form / Preparation
Most common forms and preparations reported
Legal Status
| Country | Status | Notes |
|---|---|---|
| United States | In the United States, 5-MeO-DPT is considered a Schedule I controlled substance as a positional isomer of 5-MeO-DiPT. |
Harm Reduction
drugs.wiki• Human data are sparse. Shulgin trialed 4–8.4 mg orally with onset at 12–60 min and total 2–4 h; he described mixed/ambiguous effects. Treat potency and individual variability with caution; start low and do not redose until you have fully assessed the first dose.
• Accurate dosing matters: active in low milligrams. Use a 1 mg‑resolution scale and prefer volumetric dosing (e.g., dissolve a weighed amount to a known mg/mL). Avoid eyeballing crystals or “match‑head” measures. Erowid and TiHKAL emphasize low‑mg ranges in this family.
• Route differences: vaping freebase starts within seconds and can overshoot easily; pre‑load measured doses and avoid back‑to‑back inhales. Vaped tryptamines are lung‑irritating; 5‑MeO‑DMT pages warn of respiratory harshness that generalizes to this class.
• Interactions: 5‑MeO tryptamines interact unpredictably with MAOIs and can be dangerous; TripSit combination guidance flags 5‑MeO‑xxT + MAOI as high‑risk and cautions with stimulants and tramadol. Avoid serotonergic polypharmacy.
• Serotonin‑toxicity mechanism inference: for 5‑MeO‑DMT, MAO‑A inhibition (e.g., harmaline) sharply increases systemic/brain levels; CYP2D6 status also alters bufotenine formation. While 5‑MeO‑DPT data are lacking, structural/biotransformation parallels argue for extra caution with MAOIs and CYP2D6 inhibitors.
• Sensory profile: reports often mention a high‑pitched auditory tone or “bells,” body/jaw tension, anxious come‑ups, modest visuals at common doses, with more effects as dose increases. Shulgin explicitly noted alternating “bells” vs. “turn‑on” at 8.4 mg. Loud, complex audio environments can be unpleasant.
• Storage and stability: like related 5‑MeO tryptamines, store airtight, cool, dry, and dark. Erowid’s 5‑MeO‑DiPT guide advises such storage; one BlueLight report suspected degradation in a room‑temperature solution—avoid long‑term liquid storage.
• Product uncertainty: 5‑MeO‑DPT has appeared sporadically on the NPS market. Mislabeling in this space is common (e.g., 5‑MeO‑DMT sold as DMT); only lab methods like GC‑MS/HR‑LC‑MS can reliably distinguish isomeric 5‑MeO tryptamines. Use accredited drug‑checking services where available.
• Re‑dosing discipline: wait at least 90–120 min after an oral dose (or 20–30 min after a vaped dose) before considering more; several reports describe anxiety spikes during the first 20–40 min that resolve without escalation.
• Tolerance: cross‑tolerance with serotonergic psychedelics is expected; TripSit and community sources recommend multi‑day spacing. Heavy or consecutive‑day use can dull effects and increase adverse somatic load.
• Managing body/jaw tension: some users find pre‑event magnesium supplementation, hydration, and chewing gum reduce bruxism; evidence is anecdotal and inconsistent—avoid mega‑doses and consider a mouthguard if prone to grinding.
• Lab vs. reagent tests: common color reagents cannot distinguish 5‑MeO isomers; professional GC‑MS/LC‑MS with robust libraries is needed for confirmation and for detecting adulterants.
References
Data Sources
Cited References
- Bluelight: 5-MeO-DPT First Time Report (6 mg oral)
- Bluelight: The Small & Handy 5-MeO-DPT Thread
- Erowid: 5-MeO-DPT Experience Vault
- IUCr – 5-Methoxy-N,N-di-n-propyltryptamine Crystal Structure (2021)
- PubChem: 5-MeO-DPT (Compound 14011047)
- Shulgin – TiHKAL Entry #36 (5-MeO-DET, mentioning 5-MeO-DPT)
- TiHKAL Info – 5-MeO-DPT Chemical & Pharmacological Data
- Wikidoc – 5-MeO-DPT Dosage & Duration
- PiHKAL-info – Shulgin notes (4–8 mg trials)
- ResearchGate: review – 5-MeO tryptamine toxicity (2015)
- Reddit: r/researchchemicals – 5-MeO-DPT thread (5–13 mg vaped reports)
- Reddit: r/researchchemicals – Anyone tried 5-MeO-DPT? (qualitative feedback)
- EMCDDA: Europol Early-Warning list (appearance on NPS market)
Drugs.wiki References
- PubChem – 5‑MeO‑DPT (CID 14011047) identifiers/synonyms
- Erowid TiHKAL #36 (5‑MeO‑DET entry) – 5‑MeO‑DPT subsection (dose/onset/duration; ‘bells’)
- Erowid – 5‑MeO‑DiPT Basics & Dosage (class similarities, storage and problems)
- Erowid – 5‑MeO‑DPT Experience Index (dose/duration anecdotes)
- Bluelight – Small & Handy 5‑MeO‑DPT Thread (Shulgin quotes; auditory ‘bells’)
- TripSit – Drug Combinations (5‑MeO‑xxT with MAOIs/stimulants/tramadol guidance)
- TripSit – 5‑MeO‑DMT page (rapid onset, lung harshness generalization)
- DrugBank article – MAO‑A/CYP2D6 interplay with 5‑MeO‑DMT + harmaline (mechanistic caution by analogy)
- Drug‑Checking Community – Technology overview/limitations (GC‑MS & HR‑LC‑MS capabilities)
- Erowid – UNODC 2013 NPS report (mentions 5‑MeO‑DPT among reported NPS)
- Saferparty Zürich – 5‑MeO‑DMT sold as DMT (mislabeling risk; generalizable caution)